Contact PD/PI: Dubinett, Steven M. OVERALL PROJECT SUMMARY/ABSTRACT The UCLA Clinical and Translational Science Institute is a research partnership of UCLA-Westwood, Cedars- Sinai Medical Center, Charles R. Drew University of Medicine and Science and the Los Angeles Biomedical Institute at Harbor UCLA Medical Center. Its mission is to bring biomedical innovations to bear on the greatest health needs of Los Angeles?the largest and one of the most ethnically, socially and economically diverse counties in the United States. In doing so, our goal is to become a leading contributor in the CTSA Consortium and speed scientific translation to benefit the nation as a whole. The CTSI has five aims: (1) Prepare the translational workforce to conduct high-quality, multidisciplinary team science; (2) Engage stakeholder communities in clinical and translational research and disseminate successful models of collaboration; (3) Integrate special populations, especially those experiencing health disparities, into research; (4) Improve methods and processes to accelerate scientific translation, overcome key roadblocks and support multisite research; (5) Provide informatics solutions to operational and scientific roadblocks to advance high-impact translational science within the UCLA CTSI and the CTSA network. Our novel infrastructure includes: The Los Angeles Data Resource (LADR), a federation of clinical data warehouses from six Los Angeles institutions; its governance agreement serves as the model for the CTSA ACT initiative; an Innovation and Implementation Core with Los Angeles County, a laboratory for testing approaches for improving care for the nearly 700,000 people annually treated in the county health system; a Precision Medicine program that forms the infrastructure to bring genomic-level diagnosis to translational investigation and clinical care across our UCLA Hub, multiple CTSAs and partner institutions; a training program that integrates entrepreneurship principles in on-the-job training experiences in which investigators are guided to utilize their own findings as they bring their discoveries to products. We propose to transform our CTSI from a high-functioning service organization into a well-integrated research accelerator that will develop, demonstrate and disseminate novel solutions to translational roadblocks, to the ultimate benefit of the Los Angeles community, our region and the nation. Project Summary/Abstract Page 745 Contact PD/PI: Dubinett, Steven M. OVERALL

Public Health Relevance

Residents of Los Angeles County are disproportionately young, poor and sick. Nearly one in three is under age 18 and one in five is below the federal poverty line. One in four lacks health insurance. Rates of premature death and disability far exceed national averages. The disease burden is magnified by language barriers, cultural beliefs, poverty and disparities in access to care. The goal of this work is to bring biomedical innovations to bear on the greatest health needs of Los Angeles?the largest and one of the most ethnically, socially and economically diverse counties in the United States. Project Narrative Page 746

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
1UL1TR001881-01
Application #
9261167
Study Section
Special Emphasis Panel (ZTR1-SRC (99))
Program Officer
Talbot, Bernard
Project Start
2016-07-01
Project End
2021-05-31
Budget Start
2016-07-01
Budget End
2017-05-31
Support Year
1
Fiscal Year
2016
Total Cost
$14,788,027
Indirect Cost
$3,613,524
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Tao, Yu; Yen, Ming-Ren; Chitiashvili, Tsotne et al. (2018) TRIM28-Regulated Transposon Repression Is Required for Human Germline Competency and Not Primed or Naive Human Pluripotency. Stem Cell Reports 10:243-256
Le, Steven Q; Kan, Shih-Hsin; Clarke, Don et al. (2018) A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type I. Mol Ther Methods Clin Dev 8:42-51
Bluthenthal, Ricky N; Chu, Daniel; Wenger, Lynn D et al. (2018) Differences in time to injection onset by drug in California: Implications for the emerging heroin epidemic. Drug Alcohol Depend 185:253-259
Chella Krishnan, Karthickeyan; Kurt, Zeyneb; Barrere-Cain, Rio et al. (2018) Integration of Multi-omics Data from Mouse Diversity Panel Highlights Mitochondrial Dysfunction in Non-alcoholic Fatty Liver Disease. Cell Syst 6:103-115.e7
Kamdar, Biren B; Sepulveda, Kristin A; Chong, Alexandra et al. (2018) Return to work and lost earnings after acute respiratory distress syndrome: a 5-year prospective, longitudinal study of long-term survivors. Thorax 73:125-133
Rozenman, Michelle; Vreeland, Allison; Iglesias, Marisela et al. (2018) The tell-tale heart: physiological reactivity during resolution of ambiguity in youth anxiety. Cogn Emot 32:389-396
Guedikian, Annie A; Lee, Alexandria Y; Grogan, Tristan R et al. (2018) Reproductive and metabolic determinants of granulosa cell dysfunction in normal-weight women with polycystic ovary syndrome. Fertil Steril 109:508-515
Raffield, Laura M; Ellis, Jaclyn; Olson, Nels C et al. (2018) Genome-wide association study of homocysteine in African Americans from the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Coronary Artery Risk in Young Adults study. J Hum Genet 63:327-337
Kruse, Jennifer L; Congdon, Eliza; Olmstead, Richard et al. (2018) Inflammation and Improvement of Depression Following Electroconvulsive Therapy in Treatment-Resistant Depression. J Clin Psychiatry 79:
Liu, C; Marioni, R E; Hedman, Å K et al. (2018) A DNA methylation biomarker of alcohol consumption. Mol Psychiatry 23:422-433

Showing the most recent 10 out of 287 publications